Effective antivenom is unaffordable, unavailable, or reaches rural victims too late
#00132
Rural snakebite victims in low- and middle-income countries die from envenoming that existing antivenom could treat, because effective products are priced out of reach, commercially withdrawn, absent from remote clinics, or arrived too late — an access, market, and logistics fail
Parent issue
#00074 Snakebite envenoming kills and disables hundreds of thousands each year in the rural tropics
Sustainable Development Goals
Location
Description
The problem
For a large share of snakebite deaths, an antivenom that would work already exists — but never reaches the patient at a price they can pay, in a place they can reach, in time. This covers the economics, supply chain, and last-mile delivery of antivenom, distinct from whether the science works (sibling efficacy sub-issue).
Observable evidence
- Market withdrawal despite efficacy. Sanofi-Pasteur's FAV-Afrique was widely regarded as safe and effective across sub-Saharan Africa, yet production stopped (last batch 2014, expired June 2016) after sales fell to a small fraction of the disease burden and a single dose cost more than US$100 (MSF Access Campaign; The Lancet 2015; phys.org 2019).
- Undersupply. The world produces less than half the antivenom it needs (Wellcome, 2019).
- Displacement by cheaper, inappropriate products. The gap was filled by antivenoms raised against non-local snakes; up to ~90% of antivenom in Africa is thought to be ineffective or inappropriate (Wellcome, 2019; The Conversation, 2017).
- Cold chain and distance. Most antivenoms require refrigeration, which fails in rural settings where bites occur, and victims often travel hours to a stocked facility — a delay during which neurotoxic envenoming can kill (phys.org 2019; WHO).
- Under-investment. Only an estimated £30m was invested in snakebite research across 2008–2017, before Wellcome's £80m programme launched in 2019.
Who is affected
Subsistence farming and herding households in rural Africa, South and Southeast Asia, and Latin America — least able to absorb a US$100+ out-of-pocket cost, reach a stocked hospital, or survive the delay.
Scope
Included: affordability and pricing, commercial viability, guaranteed/pooled procurement, regional manufacturing capacity, quality regulation and prequalification, cold-chain-free formulation, last-mile stocking, and pre-hospital timeliness. Excluded: the scientific question of whether a given antivenom neutralizes a given venom (sibling efficacy sub-issue).
Impact
Left unaddressed, this converts a solvable production-financing-and-logistics problem into tens of thousands of preventable deaths a year, and entrenches the neglect that keeps manufacturers out of the market.
Sub-issues
0Top solutions
3